Opus Genetics, Inc. (IRD) Stock Overview
Explore Opus Genetics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Opus Genetics, Inc. (IRD)
Key Financials
Key Financials
Market Cap
306.3M
P/E Ratio
-2.81
EPS (TTM)
$-1.18
ROE
60.69%
IRD Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Opus Genetics, Inc. (NASDAQ: IRD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Opus Genetics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of IRD on the NASDAQ shows an RSI of 52.80, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $5.85 for the NASDAQ listing.
Key metrics behind Opus Genetics, Inc.'s NASDAQ-traded stock include a P/E ratio of -2.81 and a market capitalization of 306.3M. Combined with our AI analysis, these give both institutional and retail investors a clear view of IRD on the NASDAQ.